Pyc Therapeutics
Clinical trials sponsored by Pyc Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Scientists track vision loss in rare genetic eye disease to pave way for future treatments Results expected Sep 2026 (estimated)
-
New eye injection shows promise for rare Blindness-Causing gene mutation
Disease control CompletedThis early-stage study tested the safety of a new drug called VP-001, given as an injection into the eye, for people with a rare genetic eye disease (PRPF31 mutation) that causes vision loss. Six participants aged 12 and older received multiple doses. The main goal was to check f…
Phase 1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New eye injection shows promise for rare Blindness-Causing gene mutation
Disease control CompletedThis early-stage study tested a new drug, VP-001, given as an injection into the eye to see if it is safe for people with a rare genetic eye disease caused by a PRPF31 mutation. Seventeen adults took part. The main goal was to check for side effects, not to measure vision improve…
Phase 1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC